Keryx Biopharmaceuticals KERX

By VFC : Many market analysts and economic pundits have predicted over the past few months that the record-setting highs - although nice while they lasted - would only be short-lived and a pullback or outright market correction was in store. Stocks proved overly resilient, though, and despite some

… Biopharmaceutical’s ( KERX ) Q1 2013 Earnings Call May 8, 2013 ..... Greetings and welcome to the Keryx Biopharmaceuticals Investor Conference Call ..... Financial Officer for Keryx Biopharmaceuticals . Thank you. Mr. Oliviero ..... conference call regarding Keryx Biopharmaceuticals ’ First Quarter 2013 Financial …

… By George Rho : The shares of Keryx Pharmaceuticals (NASDAQ: KERX ) almost tripled in price in the final four days of January ..... expensive anemia-treating drugs like Amgen's ( AMGN ) Epogen. KERX shares have retreated considerably from the January 31st highs …

Keryx ( KERX ): Q1 EPS of -$0.03 misses by $0.02 . Revenue of $7M beats by $1.17M . ( PR ) Post your comment!

By WhisperNumber : Keryx Biopharmaceuticals ( KERX ) is expected to report earnings on Wednesday, May 8th ..... number is -$0.01, in-line with the analysts' estimate. KERX has a 33% positive surprise history (having topped the whisper …

… just look at the last year alone, there have been countless valuation-changing moves in biotechnology. Keryx Biopharmaceuticals ( KERX ) saw a two-day period where its stock more than doubled after reporting Phase 3 data. Sarepta Therapeutics …

… USPTO. The conference call centered around Keryx Biopharmaceuticals ( KERX ) and its lead drug candidate, Zerenex ..... To read PropThink's previous coverage of Keryx Biopharmaceuticals , click here . David : Welcome to PropThink …

… article was published here . The story with Keryx BioPharmaceuticals ( KERX ) continues to evolve. I like the potential ..... Biogen Idec Inc. ( BIIB ). The story behind KERX In January, KERX released top-line Phase III about its drug …